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ABSTRACT
Random integration is one of the more straightfor-
ward methods to introduce a transgene into human
embryonic stem (ES) cells. However, random
integration may result in transgene silencing and
altered cell phenotype due to insertional mutage-
nesis in undefined gene regions. Moreover, reliabil-
ity of data may be compromised by differences
in transgene integration sites when comparing
multiple transgenic cell lines. To address these
issues, we developed a genetic manipulation
strategy based on homologous recombination and
Cre recombinase-mediated site-specific integra-
tion. First, we performed gene targeting of the
hypoxanthine phosphoribosyltransferase 1 (HPRT)
locus of the human ES cell line KhES-1. Next, a
gene-replacement system was created so that a
circular vector specifically integrates into the
targeted HPRT locus via Cre recombinase activity.
We demonstrate the application of this strategy
through the creation of a tetracycline-inducible
reporter system at the HPRT locus. We show that
reporter gene expression was responsive to
doxycycline and that the resulting transgenic
human ES cells retain their self-renewal capacity
and pluripotency.
INTRODUCTION
The capacity for long-term self-renewal and diﬀerentiation
into virtually all cells and tissues of the adult body make
ES cells powerful tools in regenerative medicine and the
creation of disease models. In theory, genetic manipula-
tion of human ES cells (hESCs) can give rise to cell lines
that that allow lineage tracking or the expression of
disease genes for use in drug screening applications.
A number of delivery methods have been used to intro-
duce genetic material into hESCs. These approaches
include DNA delivery by electroporation, nucleofection,
chemical-based reagents, or viruses (1,2). Once delivered
into the cell, genetic material can integrate randomly or in
a site-speciﬁc manner. It is thought that non-homologous
end joining (NHEJ) and homologous recombination (HR)
DNA-repair pathways mediate random integration and
site-speciﬁc integration, respectively. NHEJ is believed to
occur at a higher frequency than HR(3), making it rela-
tively easier to obtain hESCs clones that carry a randomly
integrated transgene. However, random integration may
take place in heterochromatin, leading to silencing (4) or
in coding regions, causing disruption of an endogeneous
gene or interference in the transcription of neighboring
sequences (5,6). Hence in certain applications, it is of
beneﬁt to use HR-based approaches. To date, only a few
groups have reported gene targeting in hESCs (7–14) and
eﬃciencies from non-viral based methods have yet to
approach those observed in mouse ES cells. This can
partly be attributed to the relative sensitivity of hESCs
to physical disruption and perhaps, yet to be identiﬁed
diﬀerences between mouse and hESCs.
In this study, we developed an eﬃcient method to
introduce transgenes into a deﬁned locus in hESCs.
Speciﬁcally, we performed gene targeting to introduce a
LoxP-docking site, into the HPRT locus in the female
hESC line, KhES-1. The resultant clones can then be
used in a second round of recombination using the
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presence of hygromycin, survival is highly skewed towards
clones that underwent the correct recombination event.
This is because our method requires reconstitution of
the hygromycin resistance gene by Cre-mediated recombi-
nation between (i) the EF1a promoter-ATG sequence in a
plasmid vector carrying the transgene of interest, and (ii) a
promoterless hygromycin resistance gene lacking a start
codon in the targeted HPRT locus. This method enables
integration of any gene of interest into the HPRT locus
with high eﬃciency and low background. Using this
approach, we integrated a tetracycline (Tet)-inducible
reporter and successfully introduced all components of
the Tet-On system (15) into a deﬁned site at the HPRT
locus. The hESC clones generated from this process
exhibit faithful transgene expression and retain both
self-renewal capacity and pluripotency.
MATERIALS AND METHODS
Culture of hESCs
The hESC line KhES-1 was maintained in Primate ES
medium (ReproCELL, Japan) supplemented with 5ng/
ml recombinant human basic ﬁbroblast growth factor
(bFGF, WAKO, Japan). Mouse embryonic ﬁbroblasts
(MEFs) were mitotically arrested with mitomycin C and
used as feeder cells. hESCs were passaged every 3–5days
by partial dissociation with CTK solution composed of
1mg/ml collagenase, 0.25% trypsin, 20% knockout
serum replacement (KSR, Invitrogen) and 1mM CaCl2
in phosphate-buﬀered saline (PBS).
Homologous recombination
To generate the HPRT-targeting vector, the 50- and
30- homologous arms (7.0 and 2.0kb, respectively) were
ampliﬁed from KhES-1 genomic DNA by polymerase
chain reaction (PCR). Primers used to generate the
50homology arm were as follows: AAAGCGGCCGCGA
TCCTCCCACCTCAACCTCCCAAGCAG (linked to a
NotI site) and AAAGTCGACTGCTCAGGAGGAGG
AAGCCGGTGGCGG (linked to a SalI site). The 30
homology arm was generated using the following
primers: TTTCACCGGCGCCCTGGCGTCGTGGTGA
GCAGCTCGGCCTG (linked to a SgrAI site) and TTTG
GCGCGCCTTGCACTGAGCCGAGATCATGCCACT
GTAC (linked to a AscI site). The PCR products were
then introduced into the cloning vector, pGEM T-Easy
(Promega) and the fragments were subsequently cloned
into pBluescriptII SK( ). The DNase I-hypersensitive
site 4 (HS4) of the chicken b-globin locus was isolated
from pJC5-4 (16) and used as an insulator. The
hygromycin resistance gene lacking an initiation codon
was PCR ampliﬁed from pcDNA/FRT (Invitrogen) and
introduced into a cloning vector. The targeting vector was
linearized by NotI. For electroporation, two conﬂuent
100-mm dishes of KhES-1 (2–4 10
6cells) were com-
pletely dissociated using 0.05% trypsin and 0.2mM
EDTA. Cells were mixed with 10mg of linearized-targeting
vector, electroporated in GenePulser Xcell (BioRad) using
the following settings: square mode, 250V, 4ms 2,
5s interval, and then dispensed into a 60mm dish plated
with neomycin-resistant feeders. Two days after electro-
poration, cells were treated with 50mg/ml G418.
The next day, G418 concentration was increased to
100mg/ml. Selection was performed for 10–14days
post-electroporation.
Karyotype analysis
ESCs were treated with 0.06mg/ml colcemid (Invitrogen)
for 2h, trypsinized, incubated in 0.075M KCl for 10min,
and ﬁxed in Carnoy’s ﬁxative. At least 50 spreads were
counted for chromosome number and 10 spreads were
analyzed for banding patterns at 300–500 band resolution.
Alkaline phosphatase staining and immunocytochemistry
Cells were ﬁxed with 4% formaldehyde in PBS and
alkaline phosphatase activity was detected using Vector
Blue Alkaline Phosphatase Substrate Kit III (Vector
Laboratories). The following primary antibodies were
used for immunostaining experiments: anti-Oct4 (Santa
Cruz, sc-5279), anti-stage speciﬁc embryonic antigen
(SSEA)-4 (Chemicon, MAB4304), anti-Tra-1-60
(Chemicon, MAB4360), anti-nestin (Chemicon,
MAB5326), anti-pax6 (Chemicon, MAB5552), anti-
desmin (Lab Vision, RB-9014) and anti-a-fetoprotein
(SIGMA, A-8452). Secondary antibodies were as
follows: Alexa488-conjugated goat anti-mouse IgG
(Invitrogen, A11029), Alexa555-conjugated goat anti-
mouse IgG (Invitrogen, A21424) and Alexa488-
conjugated goat anti-rabbit IgG (Invitrogen, A11034).
Gene replacement
The EF1a promoter of the pInsert vector series was
generated by PCR using pEF1/Myc-His C (Invitrogen)
as template. The insulator in pInsert vector is the
tandem core element of the chicken HS4 beta globin insu-
lator (17). The pEF1a-Cre construct was derived from
pBS185 (Addgene) with the CMV promoter replaced by
the EF1a promoter. TRE and rtTA were obtained from
pTRE-Tight (Clontech) and pTet-On (Clontech) respec-
tively by restriction enzyme digestion. Five micrograms
of pEF1a-Cre and 20mg of pInsert-Tif-CAG-EGFP or
50mg of pInsert-CTOR-EGFP were used for one
electroporation. The electroporation settings were the
same as for gene-targeting experiments. The ESCs
were then plated onto hygromycin-resistant MEFs
(Dainippon Sumitomo Pharma, Japan). Hygromycin
selection (40mg/ml, Invitrogen) was started 2days after
electroporation.
Genotyping
PCR was performed using KOD FX (TOYOBO) follow-
ing manufacturer’s recommendations. Primers used for










G-30, and P9 50-AAAATCGATTTACTTGTACAGCTC
GTCCATGCC-30. The expected sizes of PCR fragments
are as follows: P1 P2: 10.0kb, P3 P4: 5.8kb, P5 P6:
2.5kb, P5 P9: 2.6kb, P7 P8: 1.3kb. Southern blotting
was outsourced to PhoenixBio (Japan). The probe used to
identify the correct HR event was generated by PCR
ampliﬁcation using KhES-1 genome as template. Primer
sequences are as follows: 50-AATGTGTCTGATACAAC
CCATGCTGCTTGTAAC-30 and 50-AGGGAGTAAAA
TGACATGGCCTAGTTACTATC-30. EGFP cDNA was
used as a probe to assess gene replacement.
Induction of gene expression
Induction of gene expression was carried out by addition
of doxycycline (Dox) (Invitrogen) to a concentration
of 2mg/ml for 2 or 3days. In the assays for Dox
dose-dependence, cells were treated with 2mg/ml, 500, or
100ng/ml of Dox for 3days.
Flow cytometry
ESCs were dissociated by 0.25% trypsin-1mM EDTA and
then analyzed by FACS Aria (BD Biosciences) and
FlowJo software (Tomy Digital Biology, Japan).
In vitro diﬀerentiation
For embryoid body (EB) formation, hESC colonies were
detached with CTK solution, collected by sedimentation,
and seeded onto a Petri dish (BD Biosciences, 351029).
EBs were cultured in Primate ES medium (ReproCELL,
Japan) for 7days and then plated onto gelatin-coated
dishes. Adherent cells were cultured in Dulbecco’s
modiﬁed Eagle medium (DMEM, Sigma) containing
10% fetal bovine serum (FBS, JRH Biosciences) for an
additional 7days. Dox was added three days to the end
of cell culture. Cells were then harvested and analyzed by
FACS. For immunostaining with anti-nestin, 4-day-old
EBs were plated onto a poly-L-lysine/laminin-coated dish
and cultured in N2B27 neural induction medium for
12days. For immunostaining with anti-pax6, ESCs were
plated onto a poly-L-lysine/laminin-coated dish and
cultured in N2B27 neural induction medium supple-
mented with 100ng/ml mouse recombinant noggin
(R&D) and 1mM SB431542 (Sigma) for 10days. For
immunostaining with anti-desmin, 14-day old EBs were
plated onto a gelatin-coated dish and cultured in
DMEM/F12 (Sigma) containing 10% FBS for 8days.
For immunostaining with anti-a-fetoprotein (AFP),
ESCs were plated onto M15 feeder cells and cultured
in DMEM supplemented with 10% KSR, 100mM non-
essential amino acids (Invitrogen), 2mM L-glutamine
(Invitrogen), 50units/ml penicillin and 50mg/ml strepto-
mycin (Invitrogen), and 100mM b-mercaptoethanol for
14days (18). Supplementation with activin A (10ng/ml,
R&D) was performed from Day 1 to 12. Neural diﬀeren-
tiation of hESCs was carried out as described (19) with
some modiﬁcations. Brieﬂy, undiﬀerentiated hESCs were
cultured in N2B27 neural induction medium supple-
mented with both 100ng/ml mouse recombinant noggin
(R&D) and 1mM SB431542 (Sigma), an inhibitor of
TGFb signaling. After 10days, cell colonies were
dissociated into smaller clumps and cultured in N2B27
medium with noggin alone for the following 10days.
Neural progenitors were plated on poly-L-lysine, laminin
and ﬁbronectin-coated dishes, and cultured in N2B27 sup-
plemented with 10ng/ml brain-derived neurotrophic
factor (BDNF, R&D), 10ng/ml neurotrophinneuro-
trophin-3 (NT-3, R&D) and 100ng/ml nerve growth
factor (NGF, R&D) for 16days.
Teratoma formation
ES cells carrying pInsert-CTOR-EGFP were injected
into a testis of severe combined immunodeEciency
(SCID) mice (CLEA Japan). Teratomas were recovered
2 months after injection. Animal protocols were
approved by the Institutional Board on Animal Care.
Tumors were Exed in Bouin’s Exative, embedded in




We ﬁrst carried out HR in the HPRT locus of the hESC
line KhES-1. The targeting vector contained a loxP site
ﬂanked by a neomycin expression cassette (Figure 1A).
Another loxP site was located 50 to a promoterless
hygromycin resistance gene lacking the ATG codon,
with the whole construct ﬂanked by two HS4 insulators
(17). The targeting vector was delivered to KhES-1 cells by
electroporation. Out of 424 neomycin-resistant clones
screened, six (1.4%) underwent the desired HR event as
conﬁrmed by PCR genotyping (Figure 1B) and Southern
blotting (Figure 1C). One targeted clone was randomly
selected and used for subsequent gene replacement. This
clone had a normal karyotype (Figure 1D). Moreover, it
exhibited alkaline phosphatase activity (Figure 1E) and
expressed Oct4, SSEA4 and Tra-1-60, indicating mainte-
nance of an undiﬀerentiated state (Figure 1E).
Gene replacement for HPRT locus
To perform gene replacement, we constructed a vector
containing the EF1a promoter, a Kozak sequence, an
ATG codon and a LoxP site in this order (Figure 2A).
We called this vector pInsert. Co-electroporation of
pInsert with a plasmid expressing Cre recombinase and
subsequent hygromycin treatment should result in selec-
tive survival of cells that carried the pInsert vector at a
speciﬁc site in the targeted HPRT locus. Gene replacement
was performed using a pInsert vector carrying an EGFP
transgene under the control of the CAG promoter
(pInsert-Tif-CAG-EGFP) (Figure 2A). One hundred
percent of the 186 hygromycin-resistant colonies we
screened were EGFP-positive (Figure 2D). Eighty
colonies were randomly chosen from the initial 186 and
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of the neomycin cassette (Figure 2E). One clone was
randomly selected from this subset and used for succeeding
experiments. Southern blotting (Figure 2B) and PCR
(Figure 2C) conﬁrmed the correct integration of pInsert-
Tif-CAG-EGFP. This clone exhibited stable EGFP expres-
sion for at least 2months (data not shown), can form
EGFP-positive embryoid bodies (EBs) (Figure 2F) and
can diﬀerentiate into neurons (Figure 2G). All eight
clones that were randomly selected from the hygromycin-
resistant clones expressed similar levels of EGFP and
were conﬁrmed to have undergone gene replacement
(Supplementary Figure S1). We also performed gene
replacement using another targeted clone and obtained
similar results (Supplementary Figure S2A).
Inducible gene expression based on gene-replacement
system
We next attempted to introduce all components of
the Tet-inducible gene expression system into the
transgene-docking site at the HPRT locus. Gene replace-
ment was performed by co-transfection of a pInsert vector
carrying CAG-rtTA and TREtight-EGFP (pInsert-
CTOR-EGFP), with a Cre recombinase expression
plasmid (Figure 3A).
Treatment with Dox for 2days post-transfection
resulted in EGFP expression (Figure 3D and Supplemen-
tary Figure S2B). Five hygromycin-resistant clones were
randomly selected and further analyzed by Southern
blotting and were conﬁrmed to have undergone the
correct integration event (Figure 3B). All ﬁve clones
were responsive to doxycycline induction and clone #1
was further characterized. PCR analysis conﬁrmed the
integration of pInsert-CTOR-EGFP into the HPRT
locus (Figure 3C) while G-banding revealed a normal
karyotype (Figure 3E). Moreover, this clone and another
clone that was selected randomly exhibited dose-
dependent induction of EGFP expression by doxycycline,
as determined by FACS analysis (Figure 3F and
Supplementary Figure S3). Although we used a second
Figure 1. HPRT gene-targeting experiments in KhES-1 cells. (A) Scheme for HR. Ins: insulator, Hyg no ATG: hygromycin resistant gene lacking
ATG initiation codon. Arrows (P1–P4) indicate primers used for PCR genotyping. For Southern blotting experiment, the dashed lines show the
expected DNA fragment size for the WT (12.8kb) and the recombined locus (6.0kb) after Bgl II digestion. (B) Genotyping analysis to identify the
desired HR event by PCR. 50-products are 10.0kb and 30-products are 5.8kb. (C) Genotyping analysis to identify the desired HR event by Southern
blotting. (D) G-band karyotype of a KhES-1 clone that carried the targeted HPRT locus. (E) Expression of hESC markers in one of the targeted
clones. Alkaline phosphatase (ALP) activity is seen as a blue signal. Immunostaining showed expression of Oct 4, SSEA 4 and Tra-1-60.
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EGFP signals were still detected in the absence of Dox,
indicating leakiness even in this improved Tet system.
Nevertheless, treatment with 2mg/ml of Dox increased
the ﬂuorescence intensity by 15-fold compared with
the untreated control (Figure 3F and Supplementary
Figure S3).
When grown in suspension cultures, these genetically
modiﬁed hESCs formed EBs (Figure 4A), that were then
made to adhere to gelatin-coated plates. Treatment with
Dox resulted in induction of EGFP expression (Figure 4B)
in a dose-dependent manner (Figure 4C). Moreover, these
ESCs retained the ability to diﬀerentiate into representa-
tives of the three germ layers as shown by positive
immunostaining results for Nestin and Pax6 (ectoderm),
Desmin (mesoderm) and AFP (endoderm) (Figure 4D)
and can form teratomas (Figure 4E). Taken together,
these results indicate that these ESCs maintain
pluripotency after a second round of genetic modiﬁcation
and clonal selection and upon diﬀerentiation, remain
responsive to Dox.
DISCUSSION
In this study, we established a gene-replacement system
using Cre/LoxP recombination to insert any desired
cassette into the HPRT locus. This gene-replacement
strategy provides a number of advantages. First, our
method eliminates the possibility of obtaining clones
that underwent random integration of the transgene
while favoring the survival of clones carrying a correctly
integrated transgene. This is because hygromycin resis-
tance can be rescued only if the vector carrying the
transgene integrates into the targeted HPRT locus.
Moreover, the eﬃciency of Cre-mediated recombination,
calculated as the percentage of clones carrying the correct
Figure 2. Gene-replacement strategy. (A) Scheme for gene replacement. Cre recombinase-mediated integration regenerates a functional hygromycin
resistance gene while also resulting in loss of neomycin resistance. The dashed line indicates the expected fragment size after HincII digestion in the
Southern blotting. Arrows (P5–P8) are PCR primers used below. (B) Southern blotting results for one hygromycin-resistant clone using an EGFP
probe. M: Size marker, R: Clone that underwent gene replacement, P: Parental clone. (C) PCR genotyping of the hygromycin-resistant clone.
(D) EGFP expression of the hygromycin-resistant clones. (E) Neomycin sensitivity of hygromycin-resistant and EGFP-expressing clones. (F)E B
formation of the hygromycin-resistant clones. (G) Neural diﬀerentiation of a hygromycin-resistant clone.
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is about 70 times higher than that of HR-based gene tar-
geting in the original KhES-1 line (100% versus 1.4%,
respectively). This signiﬁcantly minimizes the number of
colonies to be picked and analyzed for the desired integra-
tion. Furthermore, gene targeting is performed only once
for a particular cell line to create a docking site at the
HPRT locus. Once this genetically modiﬁed parental cell
line is generated, the desired secondary recombination
event is mediated by the relatively more eﬃcient Cre
recombination system. This also eliminates the need for
long homologous sequences in the expression cassette,
hence simplifying the creation of transgenic hESCs.
We have also shown that ESCs subjected to two stages
of genetic modiﬁcation and clonal selection maintain their
pluripotency and normal karyotype. Another advantage
of our method is that site-speciﬁc integration at a
deﬁned and well-characterized locus provides a uniform
chromatin background when comparing transcriptional
activity of various promoters or the function of mutant
and normal variants of a transgene. Nevertheless, we
acknowledge that introduction of lineage reporters into
the HPRT locus may not be the ideal approach when
studying genes that require complex interactions of cis-
and trans- regulatory elements. In this case, placing the
transgene under the control the endogenous promoter
may provide a more accurate simulation of gene expres-
sion during development.
We have demonstrated faithful expression of an EGFP
gene under the control of the constitutive EF1a promoter,
in both undiﬀerentiated (Figure 2D) and diﬀerentiated
(Figure 2G) states. However, for yet to be determined
reasons, ESCs that carried the EGFP gene under the
control of the Tet system exhibited clone to clone variabil-
ity in their response to doxycycline induction (Supple-
mentary Table S1 and Figure S4). Although the
percentage of clones that exhibited satisfactory induction
is high enough to allow screening for a manageable
Figure 3. Tet-On system on the HPRT locus. (A) Scheme for generating Tet-On system on a single HPRT locus using a gene-replacement tech-
nology. pInsert-CTOR-EGFP vector contains CAG-rtTA and TRE-EGFP cassettes. After gene replacement, TRE-EGFP integrates between two
insulators. The dashed line indicates the expected band size after EcoRV digestion in the Southern blotting. Arrows (P5 and P7 to P9) are primers
used in PCR genotyping. (B) Southern blotting using an EGFP probe. M: Size marker, 1–5: Replaced clones, P: Parental clone. (C) Representative
results from PCR genotyping of surviving clones at post-selection. (D) EGFP expression of hygromycin-resistant clone #1 in the absence or presence
of Dox (2mg/ml for 2days). (E) Flow cytometric analysis of EGFP expression indicates dose-dependent response to doxycycline. Cells were treated
with 100, 500 or 2000ng/ml Dox for 3days. (F) Karyotype analysis of representative clone that underwent the desired integration.
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can further minimize time required to complete the screen-
ing. We have also shown that initial targeting of the
HPRT locus and a second recombination event that intro-
duces additional transgenes cause no adverse eﬀects on
self-renewal and pluripotency of ESCs. Nevertheless, we
could not discount the possibility that culture conditions
and selection provide a restrictive environment that ulti-
mately favors the survival of clones that are able to
self-renew and retain ES cell characteristics.
It should be noted that the HPRT locus is subject to
X chromosome inactivation. In the case of the XX hESC
line, KhES-1, hygromycin selection favors survival of
clones with an active X chromosome that carries the dis-
rupted HPRT locus. Hence it is possible for these ESCs
and their derivatives to have a Lesch–Nyhan phenotype.
Particularly in drug screening and disease model applica-
tions, it should be considered whether such phenotype
is of relevance to the cell lineage of interest and the type
of assay to be performed. Moreover, not all pInsert-
CTOR-EGFP integrated cells expressed EGFP in
response to the induction of Dox when they were
diﬀerentiated in hygromycin-free condition (Supple-
mentary Figure S5). It suggests that the manipulated X
chromosome was inactivated and that hygromycin selec-
tion is indispensable for the continuous activation of
integrated genes.
In summary, we have performed gene targeting in
hESCs to introduce a transgene-docking site into the
HPRT locus and have demonstrated high eﬃciency
Cre-mediated integration of any given construct into this
docking site. These genetically modiﬁed hESC clones
faithfully express the integrated transgenes and maintain
their self-renewal capacity and pluripotency.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Figure 4. In vitro diﬀerentiation of a clone carrying pInsert-CTOR-EGFP. (A) Thirteen-day-old EBs (phase contrast). (B) EGFP expression of
replated EBs in the absence or presence of Dox (2mg/ml for 3days). (C) Attached EBs were treated with Dox (500 or 2000ng/ml) or without Dox for
3days. Cells were then harvested and analyzed by FACS. These cells retained Dox dose-dependency in their diﬀerentiation stage. (D) Cells were
diﬀerentiated into representatives of the three germ layers and immunostained with anti-nestin (ectoderm), anti-pax6 (ectoderm), anti-desmin
(mesoderm) and anti-a-fetoprotein (AFP, endoderm). Nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI; blue). (E) Histological
analysis of teratomas formed in SCID mice.
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